SCHEMBL1996512

SCHEMBL1996512

CCn1nc(C(=O)OCc2cccc(C(F)(F)F)c2)cc(N)c1=O

nearest known ligand 0.49

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MMP1 P03956 1/20 0.49
MMP12 P39900 1/20 0.49
PRKCA P17252 1/20 0.49
PRKCD Q05655 1/20 0.49
THRB P10828 1/20 0.44
PTGER1 P34995 1/20 0.42
IDO1 P14902 2/20 0.41
MAOB P27338 5/20 0.41
MAOA P21397 1/20 0.41
ABHD6 Q9BV23 1/20 0.41
APP P05067 1/20 0.41
MAPT P10636 1/20 0.41
ADORA1 P30542 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.40
PTGDR2 Q9Y5Y4 1/20 0.40
BRD9 Q9H8M2 1/20 0.40
NR4A2 P43354 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1998314 0.85 SMN1; SMN2 (0.44) MMP12PTGER1IDO1MAOBMAOA
SCHEMBL2001144 0.85 MAPT (0.45) MAOBMAOAMAPTADORA1SMN1; SMN2
SCHEMBL1997786 0.84 KMT2A (0.47) MMP1MMP12PTGER1IDO1MAOB
SCHEMBL1998180 0.83 ALDH1A1 (0.53) MMP1MMP12THRBIDO1MAOB
SCHEMBL1999815 0.82 POLB (0.41) MAOBMAOAMAPTADORA1
SCHEMBL2000162 0.79 MAPT (0.44) MMP1MMP12PRKCAPRKCDMAPT
SCHEMBL1999844 0.79 MMP1 (0.41) MMP1MMP12PRKCAPRKCDTHRB
SCHEMBL1994640 0.78 KDM4E (0.43) MMP1MAOBMAPTSMN1; SMN2
SCHEMBL1996427 0.78 MMP9 (0.43) MMP1MMP12THRBMAOBMAOA
SCHEMBL1995154 0.77 TRPV1 (0.45) MMP1MMP12PRKCAPRKCDTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7960383-B2 phosphodiesterase enzyme inhibitor; 4-[(3-chlorophenyl)amino]-2-ethyl-5-(1-hydroxyethyl)-6-phenylpyridazin-3(2H)-one; potent antiinflammatory agent; asthma, atopic dermatitis, psoriasis, chronic obstructive pulmonary disease, rheumatoid arthritis, irritable bowel disease LABORATORIOS ALMIRALL SA (ES) 2011-06-14 US disclosed
EP-1758869-B1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS ALMIRALL SA (ES) 2010-12-22 EP disclosed
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors ALMIRALL PRODESFARMA, SA (ES) 2008-11-13 US disclosed
EP-1758869-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS Almirall Prodesfarma, S.A. (ES) 2007-03-07 EP disclosed
WO-2005123692-A1 PYRIDAZIN-3(2H)-ONE DERIVATIVES AND THEIR USE AS PDE4 INHIBITORS LABORATORIOS ALMIRALL, S.A. (ES) 2005-12-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080280918-A1 Pyridazin-3(2H)-One Derivatives and Their Use as Pde4 Inhibitors PDE12, PDE4A, PDE4B MMP1 128/4885MMP12 345/4885PRKCA 1116/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.